Regulation (EC) No 1901/2006

E563353

Regulation (EC) No 1901/2006 is the European Union’s Paediatric Regulation, establishing rules to ensure that medicines for children are researched, developed, and authorized to the same high standards as those for adults.

All labels observed (3)

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf EU paediatric regulation
European Union regulation
abbreviation PUMA for paediatric use marketing authorisation
adoptedBy Council of the European Union
European Parliament
adoptionDate 2006-12-12
aimsToPrevent delays in authorisation of medicines for adults
unnecessary clinical trials in children
amends Directive 2001/83/EC
Regulation (EEC) No 1768/92
appliesTo medicinal products for human use
paediatric population
contains requirements for labelling and package information for paediatric medicines
requirements for paediatric clinical trials
requirements for pharmacovigilance in paediatric use
definesTerm paediatric population
entryIntoForceDate 2007-01-26
establishesBody Paediatric Committee
geographicalScope all EU Member States
introducesInstrument paediatric investigation plan
jurisdiction European Union
languageOfTitle all official EU languages
legalBasis Treaty establishing the European Community
linked to: Treaty of Rome
legalNature directly applicable in all EU Member States
mainObjective to improve the health of children in the European Union
monitoredBy European Medicines Agency
national competent authorities of Member States
objective to ensure that medicines for children are appropriately authorised
to ensure that medicines used to treat children are subject to high quality research
to improve information on medicines for children
officialName Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use
OJIssuesNumber 378
OJPublicationDate 2006-12-27
OJSeries L
PaediatricCommitteeAbbreviation PDCO
PaediatricCommitteeHostedBy European Medicines Agency
paediatricPopulationAgeRange 0 to 18 years
policyArea pharmaceuticals
public health
providesIncentive paediatric use marketing authorisation
six-month extension of the supplementary protection certificate
two-year extension of orphan market exclusivity
publishedIn Official Journal of the European Union
relatedTo clinical trials in children
orphan medicinal products
requires paediatric investigation plan for most new marketing authorisation applications
requiresComplianceFrom pharmaceutical companies
shortName Paediatric Regulation
subjectToEvaluation European Commission reviews

How these facts were elicited

Referenced by (5)

Full triples — surface form annotated when it differs from this entity's canonical label.

Paediatric Regulation officialName Regulation (EC) No 1901/2006
Regulation (EC) No 1902/2006 amends Regulation (EC) No 1901/2006
Regulation (EC) No 1902/2006 relatedInstrument Regulation (EC) No 1901/2006 on medicinal products for paediatric use
linked to: Regulation (EC) No 1901/2006
Regulation (EU) 2019/5 amends Regulation (EC) No 1901/2006
Regulation (EC) No 1901/2006 officialName Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use
linked to: Regulation (EC) No 1901/2006